Innovations in Hemorrhage Management: Calcium Alginate, Celox, and Desmopressin as Next-generation Hemostatic Agents

INTRODUCTION: Hemorrhage continues to be the primary preventable cause of death, accounting for 87% of military deaths and 62% of civilian deaths. In war zones, delayed evacuation exacerbates the situation. The need for safer, more efficient substitutes is highlighted by the fact that conventional therapies, such as bone wax and vancomycin, can cause infection or systemic toxicity. METHODOLOGY: Recent developments in hemostatic technologies, including biodegradable waxes, chitosan-based agents, commercial dressings, calcium alginates, pharmaceutical alternatives, and plant-derived formulations, were studied. The hemostatic performance, biocompatibility, regeneration potential, and field applicability of these studies were evaluated. RESULTS: Comparative studies established QuikClot Combat Gauze (QCG) as superior to Celox Rapid (CR), achieving 100% immediate hemostasis versus 70% and reducing blood loss by 162 ± 48 mL. Calcium alginates provided multifunctionality by absorbing >500% of fluid, maintaining wound hydration, and supporting tissue regeneration. Desmopressin offered systemic hemostatic effects in von Willebrand disease and mild hemophilia A, although its broader utility was limited. DISCUSSION: Despite decades of research, hemorrhage remains the leading cause of preventable death, driving innovation in biodegradable hemostatic agents and safer alternatives to traditional treatments. Traditional bone wax increases infection rates, necessitating safer alternatives. New biodegradable wax formulations show dual hemostatic and regenerative properties. Chitosanbased agents demonstrate superior biocompatibility and effectiveness. CONCLUSION: Significant strides have been made toward safer, regenerative hemostatic treatments through the development of biodegradable and biocompatible agents. However, effectively translating laboratory advancements into trauma treatment and reducing hemorrhage-related mortality requires the integration of these technologies with improved evacuation infrastructure, evidencebased adoption, and enhanced field training.